Advertisement
News
Advertisement

Biogen gives positive data on hemophilia candidate

Wed, 10/31/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Biogen Idec (Nasdaq: BIIB) said Wednesday that an advanced study of its drug candidate for hemophilia A, the most common type of hemophilia, showed that the drug is longer-lasting than the currently-approved drug on the market in many patients, and therefore fewer injections are needed.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading